Abstract
Background Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.
Objective This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through February 02, 2025) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).
Methods Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2020 and February 02, 2025. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.
Results We included 697,733 hospitalizations of 643,063 unique patients who tested positive for a respiratory virus between October 01, 2020 and February 02, 2025.
Overall, the rate of hospitalizations associated with respiratory viruses slightly increased from late December 2024 into January 2025. Between the last week of December and the week ending January 27, there was a 3.1% increase in respiratory virus-associated hospitalizations; respiratory virus-associated hospitalizations accounted for 9.6% of all hospitalizations. There was a large increase in influenza-associated hospitalizations (+53.8%), which rose from 4.4% to 6.8% of all hospitalizations. In contrast, hospitalization rates associated with other respiratory viruses declined. The population 0-4 years old and over 65 saw similar increases in influenza-associated hospitalizations; the hospitalization rate at the end of January is 2-fold greater than last season’s peak (October 2023 – September 2024). The population over 65 also saw increases in rhinovirus-associated hospitalizations.
Discussion These data highlight a shifting landscape in respiratory virus-associated hospitalizations, with influenza emerging as the primary concern. While overall hospitalizations associated with respiratory viruses saw only a slight increase, influenza-associated hospitalizations rose dramatically across all age groups, particularly in young children and older adults. Conversely, RSV and COVID-associated hospitalizations declined, marking a shift from previous trends. These findings underscore the importance of continued surveillance and public health measures to address the evolving impact of respiratory viruses, ensuring that rising influenza activity does not place additional strain on healthcare systems.
Competing Interest Statement
All authors are employees of Truveta, Inc.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 45 C.F.R. Para. 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos